Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 5,051 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule 2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study

NCT01046253
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

NCT03762928
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06651600, midazolam, efavirenz
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Results available

Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy

NCT04074265
View directory record Official record
Conditions
Cerebral Palsy, Hip Dysplasia, Pain, Postoperative
Interventions
Ropivacaine injection, normal saline
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 30, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

NCT02570711
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
ACP-196, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Ventura, California • Fort Myers, Florida • Durham, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

NCT04991571
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose-dependent Anti-inflammatory Effects of Vitamin D in a Human Gingivitis Model

NCT00779909
View directory record Official record
Conditions
Gingivitis
Interventions
vitamin D3, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
18 Years to 64 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 30, 2026, 10:06 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

NCT07535034
View directory record Official record
Conditions
Gout
Interventions
Dotinurad, Placebo
Drug · Other
Lead sponsor
Crystalys Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 10:06 AM EDT
Not yet recruiting Phase 2 Interventional

Ginger's Therapeutic Potential in Asthma

NCT07792395
View directory record Official record
Conditions
Asthma
Interventions
Ginger Extract, Placebo
Drug
Lead sponsor
Emily DiMango, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 10:06 AM EDT
Recruiting Phase 2Phase 3 Interventional

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275
View directory record Official record
Conditions
Primary Membranous Nephropathy
Interventions
Povetacicept, Tacrolimus
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Montgomery, Alabama • Surprise, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 10:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

NCT05972564
View directory record Official record
Conditions
Obesity, Metabolic Syndrome
Interventions
Empagliflozin 25 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

NCT00876798
View directory record Official record
Conditions
Euvolemic Hyponatremia
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
66
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

A VI-0521 Study to Evaluate the Long-term Safety and Efficacy in Type 2 Diabetic Adults

NCT00600067
View directory record Official record
Conditions
Diabetes
Interventions
Phentermine/Topiramate, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

NCT02163694
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Veliparib Placebo, Veliparib, Carboplatin, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
56
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 30, 2026, 10:06 AM EDT
Active, not recruiting Early Phase 1 Interventional

Itraconazole to Prevent Recurrent Barrett's Esophagus

NCT05609253
View directory record Official record
Conditions
Barrett Oesophagitis With Dysplasia
Interventions
Itraconazole in capsule form, Itraconazole in solution form
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers

NCT00999128
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0941, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

NCT00842400
View directory record Official record
Conditions
Obesity
Interventions
Metformin, VI-0521, Sitagliptan, Probenecid
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 21, 2010 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

NCT03784079
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Placebo matching GSK3640254 Mesylate salt
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Bakersfield, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

NCT02477670
View directory record Official record
Conditions
Schizophrenia
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Cerritos, California • Garden Grove, California • National City, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 10:06 AM EDT
Terminated Phase 4 Interventional Results available

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

NCT03859869
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI)
Interventions
Pancrelipase, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 30, 2026, 10:06 AM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 2 Interventional

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

NCT00739739
View directory record Official record
Conditions
Interstitial Cystitis, Painful Bladder Syndrome
Interventions
PD 0299685 at 15mg BID, PD 0299685 at 30mg BID, placebo for PD 0299685
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
23
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 30, 2026, 10:06 AM EDT
Suspended Phase 3 Interventional

VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)

NCT04363203
View directory record Official record
Conditions
SARS-CoV-2, COVID-19
Interventions
Hydroxychloroquine, Azithromycin, Placebo oral tablet
Drug
Lead sponsor
Salomeh Keyhani MD
Federal
Eligibility
216 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 30, 2026, 10:06 AM EDT
Completed Phase 2 Interventional Results available

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

NCT01698905
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 10:06 AM EDT